ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.579,88
-0,31%
S&P 500
6.038,23
0,73%
US Dollar vs BRL
5,7655
-0,73%
Bitcoin
99.584,94
-1,81%
Brent Oil
76,04
0,90%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. NeuroBo Pharmaceuticals Inc (NRBO)

  7. NeuroBo Pharmaceuticals Inc (NRBO) Notícias

NRBO

NeuroBo Pharmaceuticals (NRBO)

NeuroBo Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NRBO
DataHoraFonteTítuloCódigoCompanhia
10/01/202510:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/12/202419:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
18/11/202410:01PR Newswire (US)NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic DiseasesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
15/11/202410:35GlobeNewswire Inc.Life Sciences Investor Forum: Presentations Now Available for Online ViewingNASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/11/202410:01PR Newswire (US)NeuroBo Pharmaceuticals to Participate in Investor Conferences in NovemberNASDAQ:NRBONeuroBo Pharmaceuticals Inc
07/11/202418:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
07/11/202410:01PR Newswire (US)NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
04/11/202410:01PR Newswire (US)NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/10/202409:01PR Newswire (US)NeuroBo Pharmaceuticals to Participate in Investor Conferences in OctoberNASDAQ:NRBONeuroBo Pharmaceuticals Inc
30/09/202409:01PR Newswire (US)NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
20/09/202417:15Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
03/09/202409:01PR Newswire (US)NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:NRBONeuroBo Pharmaceuticals Inc
21/08/202417:02Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NRBONeuroBo Pharmaceuticals Inc
14/08/202409:01PR Newswire (US)NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/08/202409:01PR Newswire (US)NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
07/08/202409:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:NRBONeuroBo Pharmaceuticals Inc
06/08/202409:01PR Newswire (US)NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
30/07/202409:01PR Newswire (US)NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01NASDAQ:NRBONeuroBo Pharmaceuticals Inc
25/07/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NRBONeuroBo Pharmaceuticals Inc
24/07/202418:11Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
18/07/202409:21Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:NRBONeuroBo Pharmaceuticals Inc
10/07/202412:11Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
26/06/202410:06PR Newswire (US)NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
25/06/202418:08PR Newswire (US)NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
24/06/202409:01PR Newswire (US)NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
22/06/202409:01PR Newswire (US)NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical ModelsNASDAQ:NRBONeuroBo Pharmaceuticals Inc
22/05/202409:01PR Newswire (US)NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, AloneNASDAQ:NRBONeuroBo Pharmaceuticals Inc
09/05/202409:01PR Newswire (US)NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
30/04/202409:01PR Newswire (US)NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in JuneNASDAQ:NRBONeuroBo Pharmaceuticals Inc
17/04/202409:05PR Newswire (US)NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:NRBO

Seu Histórico Recente

BIT
ETH
Eurotech
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios